A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
The primary objective on MRD negative remission rate. It is anticipated that approximately 4 to 12 patients in the safety phase could be evaluable for the primary efficacy endpoint. The additional patients needed to address the primary efficacy endpoint will be enrolled at the selected RP2Ds in the expansion phase.
The primary objective on MRD negative remission rate. Assuming a 10% ineligible/inevaluable rate, 24 eligible patients with R/R infant KMT2A-R ALL patients may be enrolled to meet this target accrual. This includes the patients with R/R infant KMT2A-R ALL enrolled at RP2D-L and RP2D-M in the safety phase who receive at least one dose of SNDX-5613.
- Rutgers Cancer Institute of New Jersey
- RWJBarnabas Health
- Newark Beth Israel Medical Center
Inclusion Criteria
- Patients must be 1 month to < 6 years old at the time of study enrollment and must
have had initial diagnosis of leukemia at < 2 years old.
- Patients must have KMT2A-rearranged acute lymphoblastic leukemia (ALL), acute leukemia
of ambiguous lineage (ALAL), or mixed phenotype acute leukemia (MPAL), which is
determined to be refractory or in first marrow relapse. All patients must undergo
cytogenetics and fluorescence in situ hybridization (FISH) testing of a
relapsed/refractory blast sample at a Children's Oncology Group (COG)-approved
laboratory for KMT2A-R status determination and the presence of a KMT2A- rearrangement
must be confirmed by central review. Cytogenetics results must be submitted for
central review by Day 10 of protocol therapy, for confirmation of KMT2A-R status.
Patients enrolled with refractory disease may utilize initial diagnostic cytogenetics
for eligibility and submission for central review if testing was performed at a COG
approved laboratory. Patients will be eligible to remain on protocol therapy if
KMT2A-R is confirmed by central review. Additional methods of assessing for KMT2A-R
may be considered if FISH does not detect the rearrangement.
- Disease status at time of enrollment must be one of the following:
- First relapse: Any recurrence of marrow disease, with or without other
extramedullary sites(s), at any point after achieving remission. ("Remission-1",
per definition below) meeting one of these criteria:
- Relapse M1: M1 morphology (< 5% blasts) + at least 2 confirmatory tests
showing >= 1% blasts (testing includes flow, cytogenetics, polymerase chain
reaction [PCR]/next-generation sequencing [NGS] of immunoglobulin
[Ig]/T-cell receptor [TCR] rearrangement, and/or PCR or NGS of fusion gene
identical to diagnosis), OR
- Relapse M2: M2 morphology (5-25% blasts) + 1 confirmatory test showing > 1%
blasts, OR
- Relapse M3: M3 morphology (> 25% blasts)
- Refractory, or failure to achieve Remission-1: Remission-1 is defined as < 1%
marrow blasts by flow minimal residual disease (MRD) and resolution of
extramedullary disease by the end of Consolidation, or 2 courses of frontline
chemotherapy.
- Central Nervous System (CNS) disease: Patients must have CNS1 or CNS2 status and no
clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial
palsy.
- Patients with CNS3 disease may receive antecedent intrathecal chemotherapy to
achieve CNS1 or CNS2 status prior to enrollment.
- Patients with a history of CNS chloromatous disease are required to have no
radiographic evidence of CNS disease prior to enrollment.
- White blood cell (WBC) must be < 50,000/uL at the time of study enrollment. Patients
can receive cytoreduction with hydroxyurea and/or corticosteroids for up to 7 days
prior to enrollment.
- Patients >= 12 months of age must have a performance status by Lansky Scale of >= 50%.
- Patients must be able to take enteral medications. Acceptable routes of administration
for SNDX-5613 include: oral (PO), nasogastric (NG) tube, nasojejunal (NJ) tube,
nasoduodenal (ND), and gastrostomy tube (G-tube).
- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive:
- >= 14 days must have elapsed after the completion of other cytotoxic
therapy, including patients who relapse during pre-Maintenance upfront
therapy, with these specific exceptions: cytoreduction with hydroxyurea
and/or corticosteroids, and intrathecal chemotherapy, which have no required
washout periods. For patients who relapse during upfront Maintenance
therapy, >= 7 days must have elapsed after the last dose of chemotherapy.
Additionally, patients must have fully recovered from all acute toxic
effects of prior therapy.
- NOTE: Cytoreduction with hydroxyurea and/or corticosteroids is
permitted prior to enrollment for patients with WBC >= 50,000/uL, and
by provider discretion regardless of WBC, to reduce potential risk of
differentiation syndrome with SNDX-5613 initiation. Hydroxyurea and/or
corticosteroids may be given for up to 7 days, with no wash-out
required.
- NOTE: No waiting period is required for patients having received
intrathecal cytarabine, methotrexate, and/or hydrocortisone.
Intrathecal chemotherapy that is given up to 7 days prior to the
initiation of protocol therapy counts as protocol therapy and not prior
anti-cancer therapy. Intrathecal chemotherapy given > 7 days prior does
not count as protocol therapy.
- NOTE: Prior exposure to fludarabine and cytarabine (FLA) is permitted.
- Anti-cancer agents not known to be myelosuppressive (e.g., not associated with
reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the
last dose of agent.
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody,
and toxicity related to prior antibody therapy must be recovered to grade =< 1.
There is an exception for blinatumomab infusions, for which patients must have
been off for at least 3 days and all drug related toxicity must have resolved to
grade 2 or lower as outlined in the inclusion/exclusion criteria.
- Hematopoietic growth factors: >= 14 days after the last dose of a long-acting
growth factor (e.g., pegfilgrastim) or >= 7 days for short-acting growth factor.
For agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur. The duration of this interval must be discussed with
the study chair and the study-assigned Research Coordinator.
- Interleukins, Interferons and Cytokines (other than hematopoietic growth
factors): >= 21 days after the completion of interleukins, interferon, or
cytokines
- Stem cell infusions (with or without total body irradiation (TBI):
- Allogeneic (non-autologous) bone marrow or stem cell transplant, or stem
cell boost: >= 84 days after infusion
- Donor leukocyte infusion: >= 28 days
- Cellular Therapy: >= 28 days after the completion of any type of cellular therapy
(e.g., modified T cells, natural killer [NK] cells, dendritic cells, etc.)
- Radiation Therapy (XRT)/External Beam Irradiation including protons: >= 14 days
after local XRT; >= 84 days after TBI, craniospinal XRT or if radiation to >= 50%
of the pelvis; >= 42 days if other substantial bone marrow radiation.
- A serum creatinine based on age as follows:
- Age 1 month to < 6 months: maximum serum creatinine 0.4 mg/dL
- Age 6 months to < 1 year: maximum serum creatinine 0.5 mg/dL
- Age 1 to < 2 years: maximum serum creatinine 0.6 mg/dL
- Age 2 to < 6 years: maximum serum creatinine 0.8 mg/dL OR
- a 24-hour urine Creatinine clearance >= 70 mL/min/1.73 m^2 OR
- a glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2. GFR must be
performed using direct measurement with a nuclear blood sampling method OR
direct small molecule clearance method (iothalamate or other molecule per
institutional standard).
- NOTE: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates
are not acceptable for determining eligibility.
- A direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, unless disease
related
- Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L
(3 x ULN) unless disease related.
- Note: For the purpose of eligibility, the ULN for SGPT (ALT) has been set to the
value of 45 U/L
- Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by
radionuclide angiogram.
- Corrected QT interval using Fridericia formula (QTcF) of < 450 msec (using the average
of triplicate measurements)
- NOTE: There are no specific electrolyte parameters for eligibility. However, it should
be noted that, to limit QTc prolongation risk, patients must maintain adequate
potassium and magnesium levels to initiate and continue SNDX-5613 on protocol therapy.
- Patients must be able to comply with the safety monitoring requirements of the study,
in the opinion of the treating investigator.
Exclusion Criteria
- Patients with isolated extramedullary leukemia.
- Patients diagnosed with Down syndrome.
- Patients known to have one of the following syndromes:
- Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome,
Shwachman syndrome, or any other known bone marrow failure syndrome.
- Patients with a secondary KMT2A-R leukemia that developed after treatment of prior
malignancy with cytotoxic chemotherapy.
- Patients with a history of congenital prolonged QT syndrome, congestive heart failure
or uncontrolled arrhythmia in the past 6 months prior to study enrollment.
- Patients with an active, uncontrolled infection, further defined below:
- Positive bacterial blood culture within 48 hours of study enrollment
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with
clinical signs of infection. Fever that is determined to be due to tumor burden
is allowed if patients have documented negative blood cultures for at least 48
hours prior to enrollment and no concurrent signs or symptoms of active infection
or hemodynamic instability
- A positive fungal culture within 30 days of study enrollment or active therapy
for presumed invasive fungal infection
- Patients may be receiving IV or oral antibiotics to complete a course of therapy
for a prior documented infection as long as cultures have been negative for at
least 48 hours and signs or symptoms of active infection have resolved. For
patients with Clostridium (C.) difficile diarrhea, at least 72 hours of
antibacterial therapy must have elapsed and stools must have normalized to
baseline
- Active viral or protozoal infection requiring IV treatment
- Human immunodeficiency virus (HIV)-infected patients are eligible if on effective
anti-retroviral therapy that does not interact with planned study agents and with
undetectable viral load within 6 months of enrollment.
- Patients with active acute graft-versus-host disease (GVHD) > grade 0 (unless skin
only), or chronic GVHD > mild (unless skin only) are not eligible. Patients with acute
or chronic skin GVHD that is =< grade 1, or chronic skin GVHD that is graded as mild
are eligible.
- Patients who have received a prior solid organ transplantation.
- Patients with known Charcot-Marie-Tooth disease, if treating on Regimen A (with
vincristine).
- CYP3A4 Inhibitors or Inducers: Patients who require concomitant therapy with moderate
or strong CYP3A4 inhibitors or inducers, as these are prohibited during the
chemotherapy combination cycles. These agents should be discontinued at least 5
half-lives prior to starting protocol therapy. Concomitant use of strong CYP3A4
inhibitor -azole antifungals are permitted during the SNDX-5613 monotherapy cycles,
with appropriate SNDX-5613 dose modification.
- P-glycoprotein (P-gp) inhibitors or inducers: Vincristine is a substrate for P-gp.
Concomitant use of P-gp inhibitors or inducers with vincristine (patients receiving
Regimen A Cycle 1) should be avoided.
- Investigational Drugs: Patients who are currently receiving another investigational
drug.
- Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents
(exceptions: hydroxyurea and corticosteroids, which may be used as cytoreduction prior
to enrollment).
- Anti-GVHD Agents: Patients who are receiving cyclosporine, tacrolimus, or other
systemic agents to treat graft-versus-host disease post bone marrow transplant.
Patients should discontinue anti-GVHD agents > 7 days prior to enrollment and have no
evidence of worsening GVHD. Topical steroids are permitted.
- Patients who have previously been treated with SNDX-5613. Prior exposure to other
menin inhibitors is permitted.
- All patients and/or their parents or legal guardians must sign a written informed
consent.
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met.
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.